EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

Cheng Cui, Na Liu, Chang Chu, Shu Niu, Yang Huang, Fangqiong Li, Yaming Li, Haiyan Li, Dongyang Liu

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70092 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Cheng Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Haisco Pharmaceutical Group Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47). Serial blood/urine samples were collected for pharmacokinetic (PK) and pharmacodynamic (PD) analyses. Cofrogliptin showed no significant impact on metformin's PK and PD properties: the geometric mean ratios (GMRs, metformin + cofrogliptin/metformin) with 90% confidence intervals (CIs) for metformin AUC 0–8 h , AUC 0–12 h, C SS (max) , Ae 0–8 h and Ratio 0–8 h , were 0.872 (0.809, 0.941), 0.900 (0.834, 0.971), 0.840 (0.743, 0.950), 0.899 (0.782, 1.032), and 0.994 (0.871, 1.136), respectively; 90% CIs for plasma glucose AUEC 0–4 h , AUEC 0–0.5 h , and EC max of combination (combination vs cofrogliptin monotherapy) all fell within 0.80–1.25. Metformin did not statistically affect cofrogliptin's PK and PD properties, as the GMRs (metformin + cofrogliptin/cofrogliptin) (90% CIs) for cofrogliptin AUC over the dosing interval and C ss (max) were 1.12 (1.072, 1.169) and 1.14 (1.057, 1.220), and AUEC 0–168 h , EC max , and EC min for dipeptidyl peptidase‐4 inhibition rate were 1.01 (1.003, 1.015), 1.00 (1.001, 1.009), and 1.03 (1.005, 1.040), respectively. No deaths, serious adverse events, or severe hypoglycemia occurred. In conclusion, the combination of cofrogliptin and metformin had no clinically significant PK or PD DDIs in healthy Chinese subjects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsHumansMaleDrug InteractionsAdultFemaleChinaYoung AdultArea Under CurveHealthy VolunteersDrug Therapy, CombinationBlood Glucose

Stichwörter der Autor:innen

DPP‐4cofrogliptindrug interactionmetforminpharmacodynamicspharmacokinetics

Substanzen

MetforminHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsBlood Glucose

Autor:innen und Institutionen

  • Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inffammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, China.
  • Clinical Research Center, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), Beijing, China.
  • Haisco Pharmaceutical Group Co., Ltd, Chengdu, China.
  • Department of Pharmaceuticals Outcome and Policy, University of Florida, FL, USA.
  • Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.

Förderung

  • Haisco Pharmaceutical Group Co. Ltd

Zitieren

APA

Cui, C., Liu, N., Chu, C., Niu, S., Huang, Y., Li, F., Li, Y., Li, H., & Liu, D. (2026). Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70092

Vancouver

Cui C, Liu N, Chu C, Niu S, Huang Y, Li F, et al. Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70092

BibTeX
@article{Cui2026,
  author = {Cui, Cheng and Liu, Na and Chu, Chang and Niu, Shu and Huang, Yang and Li, Fangqiong and Li, Yaming and Li, Haiyan and Liu, Dongyang},
  title = {Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70092}
}
Kostenlos starten →